Immunological and clinical predicators for venous thromboembolism in ANCA-associated vasculitis patients: elevated natural killer cells and cardiac involvement

Read full text Summarise with VIRAT
Authors: Ruihe Wu, Yuxin Fan, Zexuan Bin, Ruqing Jin, Xin Zhang, Chong Gao, Xiaofeng Li, Caihong Wang
Cited by: 0
References: 41

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) faces a higher risk of venous thromboembolism (VTE). We aimed to identify the predicators for VTE in AAV patients, develop and validate an AAV-VTE model. 138 AAV patients were retrospectively enrolled to identify the risk factors for VTE and develop AAV-VTE prediction mode. A temporal-validation cohort was composed of 45 AAV patients to record the incidence of VTE within 18 months. It showed that AAV patients with VTE exhibited higher disease activity, more organ involvement and immune imbalance including elevated natural killer (NK) cells and reduced regulatory T (Treg) cells. The high Birmingham Vasculitis Activity Score (BVAS), cardiac involvement, elevated eosinophil and NK cells were identified as the independent predictors for VTE. These four predicators were used to establish a nomogram model to provide a visualized and individualized risk of VTE in AAV. The model demonstrated good discriminative ability and calibration. Each 10% increase in predicted probability was associated with a 1.99-fold increase in VTE odds (OR = 1.990, 95% CI = 1.599-2.646, P < 0.001). The temporal-validation also showed that it had good discrimination. The prediction model showed a clinical application value for distinguishing VTE patients and making clinical decision. We identified the immunological and clinical risk factors for VTE in AAV, especially the elevated NK cells and cardiac involvement. The AAV-VTE model might help to facilitate individualized risk prediction and support clinical decision-making in patients with AAV.

Fields of Study & Subjects

Vasculitis and related conditions Venous Thromboembolism Diagnosis and Management Systemic Lupus Erythematosus Research

Publication details

Journal / source
Arthritis Research & Therapy
Volume
28
Issue
1
Publication date
25 March 2026
Language
EN